CheckMate 026 was a randomized trial which investigated a PD-1 inhibitor, nivolumab, and platinum-based chemotherapy in a first-line metastatic NSCLC setting without selection for PDL-1 status [21]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.